ARDM.OB: Profile for ARADIGM CORP

Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. The companys activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. The companys collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD. The company was founded in 1991 and is based in Hayward, California.

Key Statistics

COMPANY WEBSITES

Home Page

Search Yahoo! for:
More on Aradigm Corp.

CORPORATE GOVERNANCE

Aradigm Corp.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 68.7% of CGQ Universe companies and 45.7% of Health Care Equipment & Services companies.

Brought to you by Institutional Shareholder Services.

View Financials

KEY EXECUTIVES

	Pay	Exercised
Dr. Igor Gonda Ph.D., 61 Chief Exec. Officer, Pres and Exec. Director	$ 380.00K	N/A
Ms. Nancy E. Pecota , 49 Chief Financial Officer, Principal Accounting Officer and VP of Fin.	$ 66.00K	N/A
Mr. D. Jeffery Grimes J.D.,M.B.A., 45 VP of Legal Affairs, Corp. Sec. and Gen. Counsel	$ 226.00K	N/A
Mr. Jonathan Rigby , VP, Bus. Devel.	N/A	N/A
Ms. Norma L. Milligin , 70 VP of HR	N/A	N/A

Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.

View Insiders

Add to Portfolio

Set Alert

Email to a Friend

•

Annual Reports

•

Sector Analysis